Harvard Apparatus Regenerative Technology, Inc. 8-K

What Happened
Harvard Apparatus Regenerative Technology, Inc. filed an 8-K disclosing two short-term bridge loans from its Chairman and CEO, Junli He. The company executed a $200,000 Bridge Note on May 8, 2026 and a further $200,000 Bridge Note on July 16, 2026, for a combined principal outstanding of $400,000 as of the filing. Each note carries an 8% annual interest rate and matures on the earlier of (a) the closing date of the company’s next capital raise that produces at least $5,000,000 in gross proceeds or (b) May 8, 2027 (May note) / July 16, 2027 (July note).

Key Details

• Lender: Junli He, Chairman & CEO (related-party transaction); terms were approved by disinterested board members.
• Amounts: $200,000 (May 8, 2026 note) + $200,000 (July 16, 2026 note) = $400,000 outstanding.
• Interest & repayment: 8% per annum (actual/360) ; payable in full at maturity or earlier capital raise trigger; prepayment allowed without penalty.
• Conversion feature: If the company issues equity raising at least $200,000 (excluding these notes) before maturity, the lender may convert outstanding principal and interest into the new equity at the purchasers’ per-unit price. Notes include customary covenants and events of default.

Why It Matters
This filing shows the company used related-party bridge financing to cover cash needs. For investors, key implications are increased short-term debt to the CEO, potential future dilution if the notes convert into equity in a subsequent financing, and the existence of specific maturity triggers tied to future capital raises. The board’s approval by disinterested members addresses governance oversight, but investors should watch for follow-on financing plans, timing of conversion triggers, and any impact on capital structure.